Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

476 - Diagnostic value of immune histochemical and molecular biological parameters in younger patients with breast cancer


20 Dec 2015


Poster presentation 2


Lola Alimkhodjaeva


Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519


L.T. Alimkhodjaeva, D.A. Nishanov, L.T. Zakirova

Author affiliations

  • Mammology, National Cancer Research Center of Uzbekistan, 100174 - Tashkent/UZ


Abstract 476


In recent years the problem of relationship between young age and breast cancer growth attracts particular attention of researchers and still takes a special place in modern oncology. The value of this problem is significantly increased in our days, as observed the increased rate of breast cancer in women of active fertile age.


The study included 180 young women with unfavorable prognostic factors: edematous-infiltrative forms, multicentric tumor growth, angiolymphatic invasion, 3-grade tumor. All patients underwent immunohistochemical investigation with the study of ER, PR, HER2 / neu HER2 / neu, Ki67, VEGF.


During the research the following results have been obtained: 53% of patients have no oncoprotein HER2 / neu-, 22% of patients with HER2 / neu +, 10% of patients with HER2 / neu ++ , 15% of patients with HER2 / neu +++. On receptor status examination we revealed ER- and PE- in 71% of patients, while 47% of patients had ER + and PR +. In the study of vascular endothelial growth factor VEGF we determined that VEGF- was in 32% of patients, and 66% of patients were with VEGF +. We examined the relationship of vascular endothelial factor VEGF with oncoprotein HER2 / neu. As a result, we found that in group of patients with VEGF- HER2 / neu- was in 37% of patients, HER2 / neu + in 29%, HER2 / neu ++ in 19% of patients, HER2 / neu +++ in 15% of patients. In group of patients with VEGF +, HER2 / neu- was in 32% of patients, HER2 / neu + in 29% of patients, HER2 / neu ++ in 22% of patients, HER2 / neu ++ + in 17% of patients, respectively. When studied proliferative activity Ki67 we revealed that 55.6% patients had Ki-67> 25% and 44.3% of patients had Ki-67 <25%.


Lack of estrogen and progesterone receptors on the surface of tumor cells is characterized by a high-grade tumor and aggressive course of the disease. The maximum expression of NER-2neu in breast cancer cells is an independent predictor of the clinical course of the disease and is associated with high metastatic potential. The phenotype of breast cancer that characterized by a number of adverse factors ER-, PR-, NER-2neu-, have more aggressive malignant course and an unfavorable prognosis in terms of clinical course and response to specific treatment.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings